Bio-TechneMEX:TECH 83 Piotroski F-Score is 7 as of Jun. 26, 2026, which is 17% above its 10-year median of 6.00. GuruFocus rates MEX:TECH with a GF Score™ of 83/100 and a GF Value™ of MXN1,117.60. The stock has 8 warning signs investors should review. Among 1,342 Biotechnology companies, Bio-Techne ranks better than 96.94% on this metric.
Good Sign:
Piotroski F-Score is 7, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Bio-Techne has an F-score of 6 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Bio-Techne's Piotroski F-Score or its related term are showing as below:
MEX:TECH'
s Piotroski F-Score Range Over the Past 10 Years
Min: 3 Med: 6 Max: 9
Current: 7
During the past 13 years, the highest Piotroski F-Score of Bio-Techne was 9. The lowest was 3. And the median was 6.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Bio-Techne Piotroski F-Score Related Terms
Bio-Techne Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Bio-Techne's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:TECH vs HALO, IBRX, NUVL: Piotroski F-Score Comparison
For the Biotechnology subindustry, Bio-Techne's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Techne Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Techne's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Bio-Techne's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Mar26) TTM:
Last Year (Mar25) TTM:
Net Income was -332.863 + 700.473 + 684.379 + 920.515 = MXN1,973 Mil. Cash Flow from Operations was 1849.046 + 506.025 + 1483.868 + 1562.732 = MXN5,402 Mil. Revenue was 5968.179 + 5256.622 + 5327.473 + 5615.653 = MXN22,168 Mil. Gross Profit was 3743.471 + 3450.764 + 3444.076 + 3755.995 = MXN14,394 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(54096.78 + 48162.608 + 46340.164 + 45422.961 + 45994.223) / 5 = MXN48003.3472 Mil. Total Assets at the begining of this year (Mar25) was MXN54,097 Mil. Long-Term Debt & Capital Lease Obligation was MXN4,980 Mil. Total Current Assets was MXN12,407 Mil. Total Current Liabilities was MXN2,764 Mil.
Net Income was 743.576 + 661.594 + 727.655 + 462.11 = MXN2,595 Mil.
Revenue was 5607.765 + 5699.515 + 6194.789 + 6468.494 = MXN23,971 Mil. Gross Profit was 3725.356 + 3603.66 + 4043.628 + 4389.43 = MXN15,762 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(45161.231 + 49535.122 + 53872.996 + 55693.562 + 54096.78) / 5 = MXN51671.9382 Mil. Total Assets at the begining of last year (Mar24) was MXN45,161 Mil. Long-Term Debt & Capital Lease Obligation was MXN8,377 Mil. Total Current Assets was MXN12,832 Mil. Total Current Liabilities was MXN3,462 Mil.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Bio-Techne's current Net Income (TTM) was 1,973.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Bio-Techne's return on assets of this year was 0.0364625. Bio-Techne's return on assets of last year was 0.05745935.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Bio-Techne's gearing of this year was 0.10373377. Bio-Techne's gearing of last year was 0.1621114.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Bio-Techne's current ratio of this year was 4.48890274. Bio-Techne's current ratio of last year was 3.70700475.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Bio-Techne's number of shares in issue this year was 157.403. Bio-Techne's number of shares in issue last year was 158.944.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Bio-Techne's gross margin of this year was 0.64933027. Bio-Techne's gross margin of last year was 0.65755961.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Bio-Techne's asset turnover of this year was 0.40978274. Bio-Techne's asset turnover of last year was 0.53077745.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
0
+
1
+
1
+
1
+
1
+
0
+
0
=
6
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Bio-Techne has an F-score of 6 indicating the company's financial situation is typical for a stable company.
Bio-Techne (MEX:TECH) has a Piotroski F-Score of 7 as of Jun. 26, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Bio-Techne and its competitors. This is 17% above median its historical median of 6.00. Over the past decade, Bio-Techne's Piotroski F-Score has ranged from 3.00 to 9.00. According to the industry distribution chart, Bio-Techne ranks #41 out of 1342 companies in the Biotechnology industry, placing it in the top 3.1%.
Is Bio-Techne's Piotroski F-Score too high?
Bio-Techne's current Piotroski F-Score of 7 is 17% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 9.00. The Biotechnology industry median Piotroski F-Score is 3.00. Bio-Techne's value of 7 is 133.3% above this industry median. Based on the distribution chart, Bio-Techne ranks #41 out of 1342 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bio-Techne has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Bio-Techne's Piotroski F-Score compare to HALO and IBRX?
According to the Biotechnology industry distribution chart, Bio-Techne ranks #41 out of 1342 companies for Piotroski F-Score. This places Bio-Techne in the top 3% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. Bio-Techne's value of 7 is 133.3% above this benchmark. Historically, Bio-Techne's own Piotroski F-Score has ranged from 3.00 to 9.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 3.00, Bio-Techne has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,342 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Techne's current Piotroski F-Score of 7 is 133.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Bio-Techne and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Techne's current Piotroski F-Score is 7, which is 17% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Techne stock overvalued right now?
Bio-Techne (MEX:TECH) has a current Piotroski F-Score of 7. The stock's GF Value™ is MXN1,117.60, compared to a current price of MXN1,090.00 — trading 2.5% below its estimated fair value. The current Piotroski F-Score is 7, which is 17% above median its 10-year median of 6.00 and 133.3% above the Biotechnology industry median of 3.00. Bio-Techne's overall GF Score™ is 83/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Bio-Techne (MEX:TECH), the current Piotroski F-Score is 7 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Techne (MEX:TECH) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Techne stock appears to be undervalued.
The current stock price of MXN1,090.00 is trading 2.5% below its estimated GF Value™ of MXN1,117.60.
Key valuation signals for MEX:TECH:
Piotroski F-Score: 7 (17% above median its 10-year median of 6.00)
GF Value™: MXN1,117.60 vs. price of MXN1,090.00 (2.5% below fair value)
Industry Position: 133.3% above the Biotechnology median (#41 of 1342)
No single metric tells the full story. See the MEX:TECH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
83GF Score
Get the complete analysis for MEX:TECH
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:TECH has been successfully added to your 
